Toxicidad del tratamiento de la hepatitis C crónica con peginterferón a (2a o 2b) y ribavirina en pacientes no tratados anteriormente

Márquez Peiró, Juan Francisco; Eugenia Valero Alcocer, Victoria; Suárez-Varela, María Morales; Llopis González, Agustín; Pérez Peiró, Carmen.
Med. clín (Ed. impr.) ; 129(16): 612-614, nov. 2007. ilus, tab
Artículo en Es | IBECS (España) | ID: ibc-63408

Documentos relacionados

  1. Improved yield of recombinant human IFN-α2b from mammalian cells using heterologous signal peptide approach.
  2. Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial.
  3. Production of a cellular product consisting of monocytes stimulated with Sylatron<sup>®</sup> (Peginterferon alfa-2b) and Actimmune<sup>®</sup> (Interferon gamma-1b) for human use.
  4. Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.
  5. Cost-Outcome Description of PEG-IFN-&#945;2b+RBV for Hepatitis C: Results Based on the Interferon Database.
  6. Clinical and interferon-modulating efficacy of a combination of rectal and topical dosage forms of interferon-&#945;2b in acute respiratory infections.
  7. Engineering a New IFN-ApoA-I Fusion Protein with Low Toxicity and Prolonged Action.
  8. Toripalimab (anti-PD-1) versus high-dose interferon-&#945;2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial.
  9. Immunogenicity of branched polyethylene glycol modified interferon alpha.
  10. The clinical features and treatment outcome of chronic hepatitis C with pegylated interferon and ribavirin in routine care.